Since the end of the 1990’s, the pharmaceutical industry has seen an increased interest in biologics, especially in the therapeutic areas of oncology and inflammation. The selection of potent and selective Mabs (monoclonal antibodies) for specific target receptors, such as Receptor Tyrosine Kinase (RTK) and G protein-coupled receptors (GPCRs), is the first step in successfully developing an antibody based drug. In addition to potent binding, some antibodies have the ability to recruit the immune system effector cells, a process known as ADCC (Antibody Dependent Cell Cytotoxicity). The ability to promote ADCC is an important attribute of successful candidates and for that reason should be sought in the final drug design.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Circulating Oxidized Mitochondrial DNA is an Index of Pyroptotic Cell Death in Patients with Myelodysplastic Syndrome.
Grace A. Ward B.S., Kathy L. McGraw PhD., Ashley A. Basiorka PhD., Alan F. List M.D.
Regulation of miRNA Switches Depends on Nucleotide Modification, Number of Target Sites and Complementarity
John Lockhart, John Canfield, Ezinne Mong, Jeffrey VanWye, Hana Totary-Jain
Correlations among the Toddler Gut Microbiome and Health Status Variables
Samia Dutra1, Maureen Groer, PhD1, Ming Ji, PhD1, Allyson Duffy, PhD1, Kathleen Armstrong, PhD2, Larry Dishaw, PhD2, Elizabeth Miller, PhD3, Alyson Yee4, Jack Gilbert, PhD4
Preloading Corneas at the Eye Bank Improves Transplant Outcomes
Extracorporeal Shock Wave Therapy in situ – a novel approach to obtain an activated fat graft
Priglinger Eleni1,2, Peterbauer Anja2,3, Wurzer Christoph1,2,4, Steffenhagen Carolin1,2, Redl Heinz1,2,4, Sandhofer Matthias5, Wolbank Susanne 1,2